Loading clinical trials...
Loading clinical trials...
The purpose of this study is to assess if 10 mg Bay 59-7939, taken once daily as a tablet, is safe and prevents blood clot which may form after a knee replacement operation.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Bayer
NCT07350499 · Arterial Thromboembolism, Venous Thromboembolism, and more
NCT07162337 · Colorectal Cancer Prevention, Colorectal Adenoma
NCT07207408 · Prevention of Pneumonic Plague Resulting From Aerosol Exposure to Yersinia Pestis
NCT07213778 · Symptomatic Venous Thromboembolism (VTE)
NCT07303816 · Venous Thromboembolism, Cancer, and more
Vienna, State of Vienna
Graz, Styria
Innsbruck, Tyrol
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions